Literature DB >> 6187822

SFR3-DR5, a monoclonal antibody with HLA-DR5 specificity.

S F Radka, C Machamer, P Cresswell, D D Kostyu, F E Ward, D B Amos.   

Abstract

We have developed a monoclonal antibody with HLA-DR5 serologic specificity. The antibody, SFR3-DR5, binds specifically to DR5-positive lymphoblastoid cell lines, and immunoprecipitates alpha- and beta-chains characteristic of DR antigens from them. Cytotoxic activity of the antibody segregates with the DR5-bearing haplotype in a family. The antibody reacted with the cells of 16 of 17 DR5 individuals and was negative on all DR5-negative cells tested. SFR3-DR5 reacted weakly with PWM-activated cells of the single DR5 individual whose B lymphocytes were unreactive with the monoclonal antibody by cytotoxicity. Possible interpretations of these results are discussed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6187822

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  14 in total

1.  Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.

Authors:  James Scott McClellan; Scott A Tibbetts; Shivaprakash Gangappa; Kelly A Brett; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.

Authors:  Rebecca L Sparks-Thissen; Douglas C Braaten; Scott Kreher; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Recognition of class II molecules by human T cells. I. Analysis of epitopes of DR and DQ molecules in a DRw11, DRw52, DQw3 haplotype.

Authors:  L K Myers; E J Ball; G Nuñez; P Stastny
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.

Authors:  Melissa Drysdale; Gwyneth Olson; Theresa M Koehler; Mary F Lipscomb; C Rick Lyons
Journal:  Infect Immun       Date:  2007-01-22       Impact factor: 3.441

5.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

Authors:  S Kovats; G T Nepom; M Coleman; B Nepom; W W Kwok; J S Blum
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  HLA-DR7-specific monoclonal antibodies and a chimpanzee anti-DR7 serum detect different epitopes on the same molecule.

Authors:  S F Radka; D B Amos; L J Quackenbush; P Cresswell
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

7.  Expression of T-lymphoblast-encoded HLA-DR antigens on human T-B lymphoblast hybrids.

Authors:  D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

8.  Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis.

Authors:  A Hiraiwa; K Yamanaka; W W Kwok; E M Mickelson; S Masewicz; J A Hansen; S F Radka; G T Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alpha-beta chain complex.

Authors:  C E Machamer; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

10.  Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection.

Authors:  Karen A Chachu; Anna D LoBue; David W Strong; Ralph S Baric; Herbert W Virgin
Journal:  PLoS Pathog       Date:  2008-12-12       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.